Stay updated on Aldesleukin and Pembrolizumab in Melanoma Clinical Trial

Sign up to get notified when there's something new on the Aldesleukin and Pembrolizumab in Melanoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Aldesleukin and Pembrolizumab in Melanoma Clinical Trial page

  1. Check
    6 days ago
    No Change Detected
  2. Check
    13 days ago
    Change Detected
    Summary
    A unified 'Locations' section was added listing Illinois, Indiana, Massachusetts, New Jersey, and New York, replacing the previous separate 'XYZ Locations' headers. The page revision updated to v3.3.3 and the 'HHS Vulnerability Disclosure' link was removed.
    Difference
    0.6%
    Check dated 2025-12-23T17:19:00.000Z thumbnail image
  3. Check
    20 days ago
    No Change Detected
  4. Check
    27 days ago
    No Change Detected
  5. Check
    42 days ago
    Change Detected
    Summary
    Publication notes were adjusted to specify that PubMed-listed publications are auto-generated and may not be related to the study. The revision tag changed from v3.2.0 to v3.3.2.
    Difference
    0.1%
    Check dated 2025-11-24T21:48:23.000Z thumbnail image
  6. Check
    49 days ago
    Change Detected
    Summary
    The notice about lapse in government funding and NIH operating status has been removed from the page. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.3%
    Check dated 2025-11-17T19:51:25.000Z thumbnail image
  7. Check
    63 days ago
    Change Detected
    Summary
    The update involves formatting and layout adjustments to the study details page and does not modify core trial information. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.4%
    Check dated 2025-11-03T13:50:29.000Z thumbnail image
  8. Check
    91 days ago
    Change Detected
    Summary
    New operating-status notice and version update to v3.2.0 are now present, replacing the previous v3.1.0; this adds important information about potential funding-related service limitations and where to check for status.
    Difference
    2%
    Check dated 2025-10-06T04:24:29.000Z thumbnail image
  9. Check
    99 days ago
    Change Detected
    Summary
    Update includes adding revision v3.1.0 and removing the Melanoma/Cutaneous Malignant category, replacing the older v3.0.2 marker.
    Difference
    0.1%
    Check dated 2025-09-28T23:41:02.000Z thumbnail image

Stay in the know with updates to Aldesleukin and Pembrolizumab in Melanoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Aldesleukin and Pembrolizumab in Melanoma Clinical Trial page.